|
Patent landscape, scope, and claims: |
Analysis of U.S. Drug Patent 4,689,338: Ofloxacin
U.S. Patent 4,689,338, issued on August 25, 1987, to Kureha Kagaku Kogyo Kabushiki Kaisha, claims the compound ofloxacin and its salts. Ofloxacin is a broad-spectrum synthetic fluoroquinolone antibacterial agent used to treat a variety of bacterial infections [1]. This analysis details the patent's scope, claims, and the resulting patent landscape.
What is the Core Invention Claimed by U.S. Patent 4,689,338?
The primary invention claimed by U.S. Patent 4,689,338 is the chemical compound ofloxacin. The patent's claims define the molecular structure and chemical identity of this compound.
-
Claim 1: The patent's independent claim defines ofloxacin by its chemical structure and name. Specifically, it claims the compound (±)-9-fluoro-2,3-dihydro-3-methyl-10-(4-methyl-1-piperazinyl)-7-oxo-7H-pyrido[1,2,3-de]-1,4-benzoxazine, and its acid addition salts [1].
-
Dependent Claims: The patent includes dependent claims that further define the invention, such as specific acid addition salts of ofloxacin. For example, claims might specify salts formed with hydrochloric acid, sulfuric acid, or organic acids [1].
The patent’s disclosure describes the synthesis of ofloxacin and its utility as an antibacterial agent, providing biological data to support its efficacy [1].
What is the Scope of Protection Afforded by the Patent's Claims?
The scope of protection for U.S. Patent 4,689,338 is centered on the specific chemical entity of ofloxacin and its acid addition salts. This means that any party making, using, selling, offering for sale, or importing ofloxacin or its acid addition salts in the United States during the patent's term could be considered infringing.
-
Chemical Identity: The claims are directed to the compound itself, irrespective of its method of manufacture or its specific therapeutic use, provided that use is within the scope of patent law. However, the disclosure emphasizes its antibacterial properties [1].
-
Salts: The inclusion of "acid addition salts" broadens the scope to cover various pharmaceutical formulations where ofloxacin is combined with pharmaceutically acceptable acids to improve solubility, stability, or bioavailability.
-
Exclusions: The patent does not claim the general class of fluoroquinolones or other antibacterial agents. It is specifically focused on the unique chemical structure of ofloxacin. It also does not claim methods of treating specific diseases as independent claims, though the disclosure provides this context.
The patent term for U.S. patents filed after June 8, 1995, is 20 years from the filing date. For patents filed before this date, like U.S. Patent 4,689,338 filed on October 26, 1984, the term was 17 years from the date of grant [2].
- Patent Term Calculation:
- Filing Date: October 26, 1984
- Grant Date: August 25, 1987
- Original Patent Term: 17 years from Grant Date
- Expiration Date: August 25, 2004 (1987 + 17 years)
Therefore, U.S. Patent 4,689,338 has expired and no longer provides exclusionary rights for ofloxacin.
What is the Historical Patent Landscape for Ofloxacin and Related Fluoroquinolones?
The patent landscape surrounding ofloxacin is complex, involving not only the compound patent but also patents covering manufacturing processes, specific crystalline forms, enantiomers, and therapeutic uses. As a foundational fluoroquinolone, ofloxacin's patent history has influenced the development and patenting strategies for subsequent generations of fluoroquinolones.
Key Patents and Developments:
-
Composition of Matter Patent (U.S. Patent 4,689,338): This patent provided the initial, broadest protection for the ofloxacin molecule itself. Its expiration in 2004 opened the door for generic competition [1].
-
Process Patents: Numerous patents likely exist covering various synthetic routes to produce ofloxacin. These patents would claim specific chemical reactions, intermediates, or purification methods. Even after the compound patent expired, companies could seek to patent improved or novel manufacturing processes.
-
Enantiomers (Levofloxacin): Ofloxacin is a racemic mixture (a 50:50 mixture of two enantiomers). The (S)-(-)-enantiomer, known as levofloxacin, possesses significantly greater antibacterial activity and a better safety profile than the (R)-(+)-enantiomer. Patents were subsequently granted for purified levofloxacin.
- U.S. Patent 5,051,417, issued in 1991, claimed levofloxacin and its pharmaceutically acceptable salts. This patent provided an extended period of exclusivity for the more active enantiomer, delaying generic entry for the pure enantiomeric form [3].
- Levofloxacin patents would have expired later than the racemic ofloxacin patent, typically around 2011 (20 years from the 1991 filing date, considering potential patent term extensions).
-
Polymorphs and Formulations: Patents may also cover specific crystalline forms (polymorphs) of ofloxacin or its salts, or specific pharmaceutical formulations designed for improved drug delivery or stability.
-
Second-Generation Fluoroquinolones: Ofloxacin paved the way for other fluoroquinolones such as ciprofloxacin, norfloxacin, and later, more potent agents like levofloxacin, moxifloxacin, and gemifloxacin. Each of these compounds and their associated intellectual property have distinct patent histories. For example:
- Ciprofloxacin (Avelox) was initially patented by Bayer AG.
- Levofloxacin (Levaquin) was developed and patented by Daiichi Sankyo and licensed to Johnson & Johnson.
Impact of Patent Expirations:
The expiration of key patents, starting with the composition of matter patent for racemic ofloxacin (U.S. Patent 4,689,338) in 2004, has led to the availability of generic versions of ofloxacin. This has significantly reduced the cost of the drug and increased market access. The subsequent expiration of patents covering levofloxacin has similarly impacted the market for that specific enantiomer.
What are the Current Market Implications and Future Patent Considerations?
Given that U.S. Patent 4,689,338 expired in August 2004, there are no active patent protections in the United States specifically tied to the composition of matter of racemic ofloxacin itself. This has resulted in a highly competitive generic market.
-
Generic Ofloxacin: The market for racemic ofloxacin is dominated by generic manufacturers. Pricing is driven by cost-efficiency in manufacturing and market share competition.
-
Levofloxacin Market: While racemic ofloxacin is available generically, the market for levofloxacin (the S-enantiomer) was protected by its own patents for a longer period. The expiration of these patents has also led to generic competition for levofloxacin.
-
Ongoing Patenting Strategies: For pharmaceutical companies, the focus has shifted from the original compound patent to:
- New Drug Applications (NDAs) for Reformulations: Developing novel delivery systems or improved formulations of existing molecules like ofloxacin or levofloxacin could potentially be patentable, offering new market exclusivity windows.
- Combination Therapies: Patents covering the combination of ofloxacin or levofloxacin with other active pharmaceutical ingredients for synergistic effects.
- New Indications: Seeking patents for the use of existing drugs in treating new diseases or conditions. However, the ability to patent new uses for known compounds can be subject to stringent novelty and non-obviousness requirements.
- Manufacturing Process Innovations: Continuous innovation in synthetic chemistry may lead to patentable improvements in the manufacturing of ofloxacin and levofloxacin, offering cost advantages or environmental benefits.
-
Competition from Newer Antibacterials: The fluoroquinolone class, including ofloxacin and levofloxacin, faces increasing challenges from newer classes of antibiotics and growing concerns about antimicrobial resistance. This influences R&D investment and market demand.
For businesses, the primary consideration regarding U.S. Patent 4,689,338 is its historical significance in establishing the market for ofloxacin. Current market access and competitive positioning depend on the status of patents for specific formulations, enantiomers, or manufacturing processes that may still be in force or are actively being developed.
Key Takeaways
- U.S. Patent 4,689,338 claimed the compound ofloxacin and its acid addition salts.
- The patent expired on August 25, 2004, ending its protection for the racemic form of ofloxacin in the U.S.
- The patent's claims were directed to the chemical structure of ofloxacin, offering broad protection against direct copying of the compound.
- Subsequent patents, such as those for levofloxacin (the S-enantiomer), provided extended exclusivity for more potent forms of the drug.
- The expiration of the original patent has led to a mature generic market for racemic ofloxacin.
- Current patent strategies in this space focus on new formulations, combination therapies, new indications, and process improvements.
Frequently Asked Questions
-
Is U.S. Patent 4,689,338 still in force?
No, U.S. Patent 4,689,338 expired on August 25, 2004.
-
What specific compound did U.S. Patent 4,689,338 claim?
The patent claimed the chemical compound ofloxacin, chemically known as (±)-9-fluoro-2,3-dihydro-3-methyl-10-(4-methyl-1-piperazinyl)-7-oxo-7H-pyrido[1,2,3-de]-1,4-benzoxazine, and its acid addition salts.
-
Does the expiration of U.S. Patent 4,689,338 mean all ofloxacin-related patents are expired?
No. While the patent for the racemic composition of matter has expired, other patents related to specific enantiomers (like levofloxacin), manufacturing processes, crystalline forms, or novel formulations may still be active or have expired more recently.
-
Who was the original assignee of U.S. Patent 4,689,338?
The original assignee was Kureha Kagaku Kogyo Kabushiki Kaisha.
-
What is the significance of levofloxacin in relation to U.S. Patent 4,689,338?
Levofloxacin is the S-enantiomer of ofloxacin. U.S. Patent 4,689,338 claimed the racemic mixture. A separate patent, such as U.S. Patent 5,051,417, was later granted for purified levofloxacin, providing distinct and extended market exclusivity for this more active form.
Citations
[1] Kureha Kagaku Kogyo Kabushiki Kaisha. (1987). Oxy-pyridine derivatives having antibacterial activity. U.S. Patent 4,689,338. Washington, DC: U.S. Patent and Trademark Office.
[2] United States Patent Law. (2024). *35 U.S. Code § 154 - Contents and term of patent treatment of patent«. Cornell Law School Legal Information Institute. Retrieved from https://www.law.cornell.edu/uscode/text/35/154
[3] Daiichi Seiyaku Kabushiki Kaisha. (1991). Optically active 9-fluoro-2,3-dihydro-3-methyl-10-(4-methyl-1-piperazinyl)-7-oxo-7H-pyrido[1,2,3-de]-1,4-benzoxazine-6-carboxylic acid and process for producing the same. U.S. Patent 5,051,417. Washington, DC: U.S. Patent and Trademark Office.
More… ↓
⤷ Start Trial
|
